A Chinese survey on clinical practice in hyperthyroidism management: comparison with recent studies and guidelines

xlomafota13 shared this article with you from Inoreader A Chinese survey on clinical practice in hyperthyroidism management: comparison with recent studies and guidelines Via radioactive iodine Endocr Connect. 2021 Aug 1:EC-21-0340.R1. doi: 10.1530/EC-21-0340. Online ahead of print. ABSTRACT OBJECTIVE: To conduct a questionnaire survey of the current clinical practice for overt hyperthyroidism in China. METHODS: An online questionnaire survey was conducted in July 2020. The two questionnaires covered 35 and 8 questions about nonpregnancy and pregnancy clinical practice for overt hyperthyroidism, respectively. RESULTS: One thousand, two hundred fifty-six physic ians participated. Chief physicians and associate chief physicians accounted for 58.6% of the participants. Approximately 95.2% of the respondents chose the thyrotropin receptor antibody (TRAb) test to clarify the etiology of thyrotoxicosis, while only 27.0% of them chose radioactive iodine uptake (RAIU). In terms of the treatment for nonpregnant patients, antithyroid drugs (ATDs) were the first choice, and most of the clinicians chose methimazole. Compared with clinicians in recent studies, Chinese physicians used serum TRAb to diagnose Graves' disease more commonly, and there were obviously more physicians preferring ATDs. For maternal hyperthyroidism, most physicians preferred propylthiouracil administration before or during the first trimester, which is consistent with the 2016 American Thyroid Association (ATA) guidelines. In terms of the initial ATD dose, monitoring of the treatment process, indications for ATD withdrawal, and treatment of special cases, the preferences of Chi nese physicians were generally consistent with the guidelines. CONCLUSION: Chinese physicians can generally follow the ATA guidelines for the diagnosis and treatment of hyperthyroidism. Moreover, there are small differences from foreign studies or the guidelines with respect to particular problems. These findings provide evidence for future clinical research in China. PMID:34382578 | DOI:10.1530/EC-21-0340 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.